Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Andernach – page 23

605 clinical trials in Andernach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Andernach at a glance
605
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

605 trials in Andernach

Open in trial search

Acarodermatitis

Recruiting

Study on Treating Scabies with Permethrin and Ivermectin for Patients with Scabies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Study on Preventing Kidney Problems in Peripheral Arterial Disease Patients Using Carbon Dioxide and Iopamidol, Iomeprol, and Iopromide During Vascular Procedures

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iodixanol
  • Sponsor:University of Leipzig

Phase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Summit Therapeutics Inc.

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not yet recruiting

Study on Rocatinlimab for Adolescents Aged 12-17 with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Immune system disorder

Not yet recruiting

Long-Term Safety Study of JNJ-77242113 in Children with Immune System Disorders

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Andernach

What the registry says about research in the country

01 Analytical, Diagnostic and Therapeutic Techniques and Equipment

Researchers in Andernach are evaluating innovative cell‑based therapies and delivery platforms aimed at repairing knee cartilage damage.

  • Safety profile of UC‑MSC applied on a collagen scaffold
  • Use of Chondro‑Gide® as a supportive matrix
  • Development of minimally invasive implantation methods
  • Implementation of quantitative outcome tools such as KOOS

Both studies are actively recruiting at the sole research site in Andernach, aiming to generate data that could inform future diagnostic and therapeutic standards.

02 Musculoskeletal Diseases

Clinical efforts focus on restoring damaged knee joint cartilage, a prevalent musculoskeletal concern.

  • Evaluation of minced cartilage implantation (AMCI) versus matrix‑associated autologous chondrocyte implantation
  • Management of full‑thickness knee cartilage lesions
  • Assessment of functional recovery through KOOS scores
  • Exploration of long‑term joint health outcomes

The trials seek to improve treatment options for patients with large cartilage injuries and reflect Andernach’s commitment to advancing musculoskeletal research.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.